Goldman Sachs senior biotechnology analyst in global investment research Chris Shibutani joins Market Domination Hosts Julie ...

However, seasoned pharmaceutical investors recognize the industry's cyclical nature. The industry's rhythm of drug development, regulatory hurdles, marketing pushes, and patent expirations means that ...

Two supercharged income stocks -- sporting yields of 5.6% and 5.8% -- have the tools and intangibles needed to catapult ...

As we move further into October, many investors may be looking to identify certain stocks with the potential to provide ...

You can find plenty of affordable stocks that offer solid long-term growth prospects. If you're interested in the healthcare ...

In a previous interview, Lee hinted that a period of market volatility is expected, as 2024 heads for a soft landing.

Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

Here are some of the major companies whose stocks moved on the week’s news.

Late afternoon on Tuesday, the Financial Times (FT) published an article stating that Pfizer CEO Albert Bourla plans to meet ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer (PFE – Research Report), with a price ...

There was some intriguing news from a Pfizer (NYSE: PFE) shareholder on Thursday that was not taken well by the market.